

SPARKS

PHARMACODYNAMIC BIOMARKERS IN BIOSIMILAR DEVELOPMENT AND APPROVAL

Recent Developments

www.accelsiors.com

Accelsiors

Introduction

Biosimilars represent a transformative opportunity for the biopharmaceutical industry, offering cost-effective alternatives to reference biologics while improving patient access to life-saving therapies. However, their development is inherently complex due to the intricate nature of biological molecules, necessitating rigorous analytical, preclinical, and clinical evaluations. Pharmacodynamic (PD) biomarkers have emerged as critical tools in this process, enabling developers to demonstrate biosimilarity more efficiently and with greater precision.

This white paper explores the evolving role of PD biomarkers in biosimilar development, highlighting recent advancements, regulatory frameworks, collaborative initiatives, and future directions. It also addresses challenges that must be overcome to fully realize the potential of PD biomarkers in streamlining biosimilar approval processes.

What Are Pharmacodynamic Biomarkers?

Definition and Distinction from PK Biomarkers

Pharmacodynamic (PD) biomarkers are measurable indicators of a drug's biological effects on physiological systems or disease pathways. Unlike pharmacokinetic (PK) biomarkers, which focus on how the body absorbs, distributes, metabolizes, and excretes a drug, PD biomarkers quantify the drug's impact on its target mechanism of action.

Examples of PD Biomarkers

Absolute Neutrophil Count (ANC)
Used in granulocyte colony-stimulating factor (G-CSF) biosimilars (e.g., filgrastim, pegfilgrastim) to assess neutrophil production.

CD34+ Cell Count
Measures hematopoietic stem cell stimulation, relevant for evaluating G-CSF (e.g., filgrastim, pegfilgrastim) biosimilars.

Glucose Infusion Rate
Reflects glucose metabolism in insulin biosimilars.

VEGF (Vascular Endothelial Growth Factor) Levels
Monitored in anti-angiogenic biosimilars (e.g., bevacizumab) to evaluate inhibition of vascular endothelial growth factor (VEGF).

These biomarkers provide surrogate endpoints that correlate strongly with clinical outcomes, allowing developers to infer therapeutic equivalence without extensive efficacy trials.

The Role of PD Biomarkers in Biosimilar Development

PD biomarkers serve as essential tools for demonstrating comparability between biosimilars and their reference products. They enable developers to:

Validate Mechanism of Action
Confirm that the biosimilar interacts with its intended target in the same manner as the originator product.

Reduce Reliance on Clinical Efficacy Trials
By providing robust evidence of comparable biological activity, PD biomarkers can replace or complement traditional efficacy studies.

Support Extrapolation Across Indications
When PD biomarkers reflect the primary mode of action across multiple indications, they facilitate extrapolation of biosimilarity claims.

Advantages of PD Biomarkers

Increased Sensitivity
PD biomarkers detect subtle differences in biological response that may not be apparent through standard clinical endpoints.

Streamlined Development
Regulatory agencies such as the FDA allow biosimilar approvals based on PK/PD similarity data in certain cases, reducing the need for large-scale clinical trials.

Cost and Time Savings
Efficient use of PD biomarkers accelerates regulatory reviews, expediting market entry for biosimilars.

Case Studies

Epoetin Alfa Biosimilars
Hemoglobin levels and reticulocyte count were used as PD biomarkers to demonstrate equivalence in treating anemia associated with chronic kidney disease (CKD).

Filgrastim Biosimilars
The use of absolute neutrophil count as a PD biomarker has been pivotal in approving biosimilars for these granulocyte colony-stimulating factors.

Bevacizumab Biosimilars
VEGF levels served as key PD biomarkers in oncology trials, ensuring similar angiogenic inhibition profiles.

bdglobal@accelsiors.com | +41 41 799 69 40 | www.accelsiors.com

Regulatory Guidelines on PD Biomarkers

Regulatory authorities worldwide recognize the importance of PD biomarkers in biosimilar development, incorporating them into stepwise approaches for demonstrating biosimilarity.

FDA's Stepwise Approach

The FDA outlines a structured pathway for biosimilar development:

Analytical Characterization
Ensures high structural and functional similarity at the molecular level.

Preclinical Studies
Uses PD biomarkers in animal models to confirm mechanism-of-action consistency.

PK/PD Studies
Demonstrates equivalence in clinical pharmacology data, often using sensitive PD biomarkers.

Clinical Immunogenicity Assessment
Evaluates safety and immunogenicity risks.

FDA Guidance
The FDA has updated its guidance to emphasize the use of pharmacokinetic (PK) and PD data in biosimilar development. The document "Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product" underscores the importance of PD biomarkers in demonstrating similar biological effects between biosimilars and reference products.

Workshops and Collaborations
The FDA, alongside academic institutions like Duke-Margolis, has engaged in dialogues through workshops like "Pharmacodynamic Biomarkers for Biosimilar Development and Approval" in 2021. These gatherings have fostered discussions on the practical application of PD biomarkers in regulatory decision-making.

Global Regulatory Perspectives

European Medicines Agency (EMA)
Emphasizes integrating PD biomarkers with advanced analytical techniques to support biosimilarity claims.

World Health Organization (WHO)
Advocates for harmonized guidelines incorporating PD biomarkers into global biosimilar development frameworks.

Health Canada
Encourages the use of PD biomarkers to minimize the burden of large clinical trials while maintaining rigorous standards.

Regulatory Evolution

Global Harmonization
Efforts are underway to align regulatory expectations globally concerning PD biomarkers, which could simplify the approval process across different markets.

Guidance Updates
New regulatory guidance will likely reflect the scientific advancements, providing clearer pathways for biosimilar approval using PD data.

Collaborative Efforts and Recent Research

Collaboration among regulatory bodies, academia, and industry is driving innovation in PD biomarker research.

Notable Initiatives

FDA-Duke-Margolis Workshops
These workshops address evidentiary strategies for PD biomarkers, fostering dialogue between stakeholders to refine methodologies.

Omics-Driven Discovery
Advances in proteomics, transcriptomics, and metabolomics are uncovering novel biomarkers with higher sensitivity and specificity.

AI Integration
Machine learning algorithms analyze complex datasets to identify patterns and correlations, enhancing the discovery and validation of PD biomarkers.

Key Innovations

Digital Health Technologies
Wearable devices and mobile health apps enable continuous monitoring of PD biomarkers in real-world settings.

Multi-Omics Platforms
Combining genomic, proteomic, and metabolomic data provides a holistic view of drug effects, improving predictive accuracy.



Challenges and Limitations of PD Biomarkers

Despite their promise, PD biomarkers face several challenges:

Variability in Response
Genetic polymorphisms, comorbidities, and environmental factors introduce variability in biomarker responses, complicating interpretation.

Limited Availability
Not all biologics have well-established PD biomarkers, creating obstacles for certain classes of biosimilars.

Resource-Intensive Assays
Developing and validating assays for PD biomarkers requires specialized expertise, infrastructure, and funding.

Regulatory Uncertainty
Establishing the "fit-for-purpose" utility of PD biomarkers remains challenging, particularly in complex therapeutic areas like oncology.

Strategies to Overcome Challenges

- Standardizing assay protocols and validation criteria.
- Leveraging multi-center collaborations to pool resources and expertise.
- Engaging regulatory agencies early in the development process to align expectations.

Future Directions in PD Biomarker Research

The future of PD biomarker research will be shaped by technological advancements, regulatory harmonization, and innovative partnerships.

Key Trends

Omics Technologies
Continued advancements in proteomics, transcriptomics, and metabolomics will drive the discovery of novel, highly specific PD biomarkers.

Integrated Approaches
Combining PD biomarkers with real-world evidence (RWE) and digital health data will enhance the evaluation of biosimilarity in diverse populations.

Global Harmonization
Increased collaboration between regulatory bodies could lead to streamlined international approval processes, facilitating broader access to biosimilars.

Emerging Opportunities

Precision Medicine
Tailoring PD biomarker selection to specific patient subgroups could improve biosimilar development for niche indications.

Decentralized Trials
Leveraging remote monitoring technologies to collect PD biomarker data in decentralized clinical trials, reducing costs and increasing accessibility.

Agency-Specific Comparison of Biomarker Regulations in Early-Phase Clinical Trials

Free Download

Regulatory Oversight of Early-Phase Clinical Trials Across Key Agencies

Free Download

Conclusion

Pharmacodynamic biomarkers are revolutionizing biosimilar development by making the process faster, more efficient, and cost-effective. Their ability to provide precise insights into a drug's biological activity enables developers to reduce reliance on extensive clinical trials while ensuring biosimilarity. As technology advances and regulatory frameworks evolve, PD biomarkers are poised to play an increasingly pivotal role in expanding access to affordable biological treatments globally.

For decision-makers in the biotech industry, investing in PD biomarker research and leveraging these tools strategically can yield significant competitive advantages, accelerating time-to-market and optimizing resource allocation. Embracing this paradigm shift will be crucial for navigating the complexities of biosimilar development in an increasingly dynamic regulatory landscape.

Ready to explore how PD biomarkers can streamline your biosimilar development strategy?



Contact Our Experts for a Consultation:
bdglobal@accelsiors.com | +41 41 799 69 40 | LinkedIn

References

[1] Niazi SK. A Critical Analysis of the FDA's Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity. Pharmaceuticals (Basel). 2023;16(11):1556.
[2] Woollett GR, Park JP, Han J, et al. The Role of PD Biomarkers in Biosimilar Development – To Get the Right Answer One Must First Ask the Right Question. Clin Pharmacol Ther. 2022;113(1):50–54.
[3] Robert M Califf. Biomarker definitions and their applications. Exp Biol Med (Maywood). 2018;243(3):213–221.
[4] Biosimilars. WHO. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards/sbp
[5] Pharmacodynamic Biomarkers: Their Role in Biosimilar Product Development. FDA: https://www.fda.gov/drugs/spotlight-cder-science/pharmacodynamic-biomarkers-their-role-biosimilar-product-development
[6] Case Study. Level 2: Regulatory Scientific Concepts. FDA: https://www.fda.gov/media/154919/download
[7] Guideline on Similar Biological Medicinal Products. EMA. https://www.ema.europa.eu/en/similar-biological-medicinal-products-scientific-guideline
[8] WHO Biosimilar Guidelines – 2022 Update: https://www.who.int/publications/m/item/guidelines-on-evaluation-of-biosimilars
[9] Prelaj A, Miskovic V, Zanitti M et al. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review. Ann Oncol. 2024;35(1):29-65.
[10] Pharmacodynamic Biomarkers for Biosimilar Development and Approval. FDA-Duke-Margolis Workshops Summary Reports. https://healthpolicy.duke.edu/events/biosimilar
[11] Ivanisevic T, Sewduth RN. Multi-Omics Integration for the Design of Novel Therapies and the Identification of Novel Biomarkers. Proteomes. 2023;11(4):34.